Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration
Author: Rhee, S.
Varghese, V.
Holmes, S.
Van Zyl, G.
Steegen, K.
Boyd, M.
Cooper, D.
Nsanzimana, S.
Saravanan, S.
Charpentier, C.
de Oliveira, T.
Etiebet, M.
Garcia, F.
Goedhals, D.
Gomes, P.
Günthard, H.
Hamers, R.
Hoffmann, C.
Hunt, G.
Jiamsakul, A.
et al.
Citation: EBioMedicine, 2017; 18:225-235
Publisher: Elsevier
Issue Date: 2017
ISSN: 2352-3964
Statement of
Soo-Yon Rhee ... Mark A. Boyd ... et al.
Abstract: Tenofovir disoproxil fumarate (TDF) genotypic resistance defined by K65R/N and/or K70E/Q/G occurs in 20% to 60% of individuals with virological failure (VF) on a WHO-recommended TDF-containing first-line regimen. However, the full spectrum of reverse transcriptase (RT) mutations selected in individuals with VF on such a regimen is not known. To identify TDF regimen-associated mutations (TRAMs), we compared the proportion of each RT mutation in 2873 individuals with VF on a WHO-recommended first-line TDF-containing regimen to its proportion in a cohort of 50,803 antiretroviral-naïve individuals. To identify TRAMs specifically associated with TDF-selection pressure, we compared the proportion of each TRAM to its proportion in a cohort of 5805 individuals with VF on a first-line thymidine analog-containing regimen. We identified 83 TRAMs including 33 NRTI-associated, 40 NNRTI-associated, and 10 uncommon mutations of uncertain provenance. Of the 33 NRTI-associated TRAMs, 12 - A62V, K65R/N, S68G/N/D, K70E/Q/T, L74I, V75L, and Y115F - were more common among individuals receiving a first-line TDF-containing compared to a first-line thymidine analog-containing regimen. These 12 TDF-selected TRAMs will be important for monitoring TDF-associated transmitted drug-resistance and for determining the extent of reduced TDF susceptibility in individuals with VF on a TDF-containing regimen.
Keywords: HIV-1; antiretroviral therapy; reverse transcriptase; drug resistance; tenofovir; WHO-recommended first-line
Rights: © 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (
DOI: 10.1016/j.ebiom.2017.03.024
Published version:
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_115973.pdfPublished Version671.29 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.